Ats Corporation · TSX:ATS
Ats — ATS Automation — Merger or Acquisition (December 2018)
9 slides from Ats's merger presentation, Dec 19, 2018
Slide 1: Comecer S.p.A. Acquisition
Comecer S.p.A. Acquisition ATS AUTOMATION TSX:ATA Investor Presentation - December 2018
Slide 2: Forward Looking Statements & Non-IFRS Measures
Forward Looking Statements & Non-IFRS Measures This presentation and the oral statements made during this meeting contain certain statements that constitute forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Such forward-looking statements in
Slide 3: Comecer At A Glance
Comecer At A Glance Business Overview Segment Overview ■ Leading manufacturer of isolators, hot cells, ■ Radiopharmaceutical: Radiation-shielded containment incubation modules, and associated equipment for the and automation equipment used in the processing, aseptic production and packaging of radio
Slide 4: Strategic Rationale
Strategic Rationale Acquisition Rationale ■ New & Highly Complementary Capabilities ■ Comecer: Strong in isolator technologies ■ ATS: Strong in robotics and automation ■ Complementary geographic presence ■ Expands Life Science Segment Penetration ■ Radiopharmaceutical sector is increasing automation
Slide 5: Comecer Product Portfolio
Comecer Product Portfolio Stand-alone products Integrated machines End-to-end production lines After-sale services ■ Standard-design ■ Custom-design ■ Custom-design ■ Maintenance ■ Isolators ■ Containment system with ■ Series of integrated machines ■ Warranty custom automation and software ■ Restric
Slide 6: Customers & Markets
Customers & Markets Customer Base Life Science Segments ■ Serves a mix of blue-chip and small/medium Radiopharmaceutical enterprises Equipment to produce: PET/SPECT radioisotopes, Alpha & Beta emitters Growth drivers: ■ Long-term agreements with anchor clients • Growing importance of early detection
Slide 7: Transaction & Financial Highlights
Transaction & Financial Highlights Transaction Details Financial Impact ■ Purchase price of €113 million or ~C$172 million* ■ Proforma leverage of ~1.0x net debt / TTM EBITDA ■ Acquiring 100% of outstanding shares ■ Adjusted EPS and CFPS accretive in first full year ■ Purchase price subject to custo
Slide 8: Acquisition Summary
Acquisition Summary Key Takeaways ATS Strategy (September 2018 Investor Day) ■ On target with capability expansion strategy in core Life Sciences market ■ Attractive end market exposure and complementary to current segments served ■ Enhanced and more comprehensive combined product offering ■ Opportu
Slide 9: ATS Automation TSX:ATA
ATS AUTOMATION | TSX:ATA
ATS Automation — Merger or Acquisition (December 2018) on 6ix